

Roman Casciano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5785981/publications.pdf>

Version: 2024-02-01

26
papers

396
citations

840776

11
h-index

752698

20
g-index

26
all docs

26
docs citations

26
times ranked

417
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. <i>Clinical Infectious Diseases</i> , 2022, 75, e450-e458.	5.8	84
2	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
3	Comparative effectiveness research in COVID-19 using real-world data: methodological considerations. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1259-1264.	1.4	2
4	Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 243-250.	1.9	18
5	Treatment patterns among patients with metastatic GEP-NET treated at a tertiary referral center.. <i>Journal of Clinical Oncology</i> , 2017, 35, 397-397.	1.6	1
6	First-Year Incidence of Double-Stranded DNA Virus Infections Following Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S169.	2.0	0
7	Clinical and Economic Consequences Associated with Cytomegalovirus Infection Among Allogeneic Hematopoietic Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S160.	2.0	0
8	First-Year Incidence of Adenovirus Infections Following Allogeneic Hematopoietic Cell Transplants in a Pediatric Population. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S170-S171.	2.0	2
9	An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. <i>Clinical Therapeutics</i> , 2015, 37, 2552-2559.	2.5	13
10	A weighted-adjusted indirect comparison of everolimus (EVE) versus axitinib (AXI) in second-line metastatic renal cell carcinoma (mRCC) patients who previously failed sunitinib therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 491-491.	1.6	1
11	Health plan budget impact of introducing everolimus for treatment of advanced progressive pancreatic neuroendocrine tumors in the United States.. <i>Journal of Clinical Oncology</i> , 2012, 30, 229-229.	1.6	0
12	Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States.. <i>Journal of Clinical Oncology</i> , 2012, 30, 226-226.	1.6	0
13	Resource utilization among neuroendocrine tumor patients in the United States.. <i>Journal of Clinical Oncology</i> , 2012, 30, 251-251.	1.6	1
14	The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. <i>Clinical Therapeutics</i> , 2008, 30, 341-357.	2.5	37
15	P176: Burden of Chronic Sinusitis: A Survey of Otolaryngologists. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 135, P270-P270.	1.9	0
16	P182: Amphotericin B Nasal Spray in Chronic Sinusitis Chart Review. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 135, P272-P272.	1.9	0
17	A Pharmacoeconomic Evaluation of Seven-Valent Pneumococcal Conjugate Vaccine in Spain. <i>Value in Health</i> , 2004, 7, 36-51.	0.3	42
18	A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. <i>European Journal of Health Economics</i> , 2004, 5, 278-284.	2.8	14

#	ARTICLE	IF	CITATIONS
19	A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. <i>International Journal of Cardiology</i> , 2004, 96, 51-57.	1.7	12
20	Cost and Effectiveness of Venlafaxine Extended-Release and Selective Serotonin Reuptake Inhibitors in the Acute Phase of Outpatient Treatment for Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 497-506.	1.4	23
21	A Pharmacoeconomic Evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom. <i>Pharmacoeconomics</i> , 2003, 21, 25-32.	3.3	19
22	A Pharmacoeconomic Evaluation of 7-valent Pneumococcal Conjugate Vaccine in Canada. <i>Clinical Infectious Diseases</i> , 2003, 36, 259-268.	5.8	52
23	Economic Benefits of Amlodipine Treatment in Patients with Coronary Artery Disease. <i>Pharmacoeconomics</i> , 2002, 20, 553-563.	3.3	6
24	A pharmacoeconomic evaluation of results from the coronary angioplasty amlodipine restenosis study (CAPARES) in Norway and Canada. <i>International Journal of Cardiology</i> , 2002, 84, 23-30.	1.7	9
25	A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs. <i>Value in Health</i> , 2001, 4, 16-31.	0.3	52
26	A pharmacoeconomic evaluation of major depressive disorder (Italy). <i>Epidemiologia E Psichiatria Sociale</i> , 1999, 8, 220-231.	0.9	6